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Clinical study on anterior ischaemic optic neuropathy
Abstract
A prospective observational study was conducted over a period of 12 months on 35 
patients presenting with typical features of anterior ischaemic optic neuropathy. 
Patients with infectious/inflammatory diseases/other disorders that could cause visual 
defect were excluded from the study. It was found that this disease mostly affects the 
elderly population with 51-60 years being the most affected age group. Females were 
found to be more affected than males with the predominance of right eye over left 
eye. Diabetes mellitus was found to be the most common associated risk factor 
followed by systemic hypertension. 69.44% of the subjects presented with poor visual 
acuity in the range of 2/60 to 6/60. Pallid disc oedema was the most common 
ophthalmoscopic finding followed by sectoral disc pallor. Superior and inferior 
altitudinal field defects were predominant among patients in whom automated 
perimetry was possible. In most of the patients, vision remained less than 6/60 despite 
timely intervention with corticosteroids. The presence of diabetes mellitus is 
associated with poor visual outcome. But hypertension and hyperlipidemia did not 
affect the visual outcome. Thus anterior ischaemic optic neuropathy must be 
considered as an important differential diagnosis of painless loss of vision in elderly 
population associated with optic disc oedema. All patients must be thoroughly 
evaluated for systemic risk factors and promptly treated to prevent the condition in the 
other eye
Keywords – anterior ischaemic optic neuropathy, pallid disc oedema, sectoral pallor, 
altitudinal visual field defect, corticosteroids, automated perimetry. 
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INTRODUCTION AND HISTORY
Anterior ischaemic optic neuropathy is a common disease which affects 
visual acuity in the adult and elderly population. The annual incidence of 
NAION is approximated to be around 2.3 to 10.2 per 100,000 for people
aged 50 years and above1. It is known to be associated with many 
circumstances that may influence and decrease the blood supply to optic 
nerve head. Some of these risk factors are diabetes, hypertension, 
hyperlipidemia, hyperhomocysteinemia and pro-thrombotic disorders.  It 
is believed to be due to circulatory insufficiency associated with blood 
supply of the anterior portion of optic nerve.          
ANATOMY AND BLOOD 
SUPPLY OF THE OPTIC 
NERVE HEAD
                                               
Fig 1: Picture depicting the anatomy of optic nerve
ANATOMY OF THE OPTIC NERVE 
The optic nerve is the second cranial nerve which begins from the optic 
disc and extends up to the optic chiasma where the two nerves meet. It is 
the backward continuation of the retinal nerve fibre layer which consists 
of axons taking origin from the ganglion cells. 
PARTS OF THE OPTIC NERVE
The optic nerve which is about 47-50 mm in length is divided into four 
parts
1. Intraocular (1mm)
2. Intraorbital (30 mm)
3. Intracanalicular (6-9mm)
4. Intracranial (10mm)
INTRAOCULAR PART
Axons of the retinal ganglion cells form bundles that constitute the nerve 
fibre layer which converges at the optic nerve head. It has an average 
horizontal diameter of 1.5 mm and vertical diameter of 1.8mm. It is a 
major zone of transition because nerve fibres pass from an zone of high 
pressure to a zone of low pressure that corelates with the intracranial 
pressure. The nerve fibres leave an area of blood supply from the central 
retinal artery to zones supplied by other branches of ophthalmic artery. 
The axons also become myelinated immediately at the posterior end of 
optic nerve head where it expands to 3mm.2
Figure 2 – picture depicting anatomy of optic nerve head
Arbitrarily the optic nerve head is divided into four portions from anterior 
to posterior -
1. Surface nerve fibre layer 
Is composed of nerve fibres of retina which converge on optic disc 
and astrocytes. The optic disc is covered by a thin layer of astrocyte-
the internal limiting membrane of Elschnig which separates it from the 
vitreous and is continuous with internal limiting membrane of retina.
2. Prelaminar region
The predominant structures at this level are neurons and a 
significantly increased quantity of astroglial tissue. The border tissue 
seaperates the nerve from the choroid.
3. Lamina cribrosa
It is a fibrillar sieve like structure made up of fenestrated sheets of 
scleral connective tissue lined by glial tissue. It bridges the posterior 
scleral formina or the scleral canal. The bundles of optic nerve fibres 
leave the eye through the fenestrations. A rim of collagenous 
connective tissue with some admixture of glial cells which intervenes 
between the choroid and sclera and optic nerve fiibres is the border 
tissue of Elschnig. 
4. Retrolaminar region
There is a decrease in astrocytes and acquisition of myelin that is 
supplied by oligodendrocytes. The addition of myelin sheath nearly 
doubles the diameter of the optic nerve as it passes through the sclera. 
The axonal bundles are surrounded by connective tissue septa.
Figure 3 – picture showing the anterior part of the optic nerve
INTRAORBITAL PART
Extends from back of eyeball to the optic nerve foramina. This part is 
slightly sinuous to allow or eye movements.
INTRACANALICULAR PART
Closely related to the ophthalmic artery which crosses the nerve inferiorly 
from medial to lateral side in the dural sheath and leaves the sheath at the 
orbital end of the canal.
INTRACRANIAL PART
Lies above the cavernous sinus and converges with its fellow to form the 
optic chiasma. This part is ensheated in piamater, but recieves arachnoid 
and dural sheaths at the point of its entry into the optic canal.
BLOOD SUPPLY OF THE OPTIC NERVE HEAD
Optic nerve recieves its blood supply from the posterior ciliary vessels 
with a small contribution from central retinal vessels3. The source and 
pattern of the blood supply of anterior part (optic nerve head) differs from 
that of the posterior part.  The optic nerve head is almost entirely supplied 
by the posterior ciliary artery circulation while the rest of the optic nerve 
posterior to it is supplied from several other sources.
Figure 4 – schematic representation of blood supply of optic nerve 
1. SURFACE NERVE FIBRE LAYER – supplied by the capillaries 
derived from the retinal arterioles, which anastomose with vessels 
of the prelaminar region. Occasionally a ciliary derived vessel from 
the prelaminar region may enlarge to form the cilioretinal artery.
2. PRELAMINAR REGION – suppiled by vessels of ciliary region. 
These vessels are derived from separate branches of short posterior 
ciliary arteries.
3. LAMINA CRIBROSA REGION – is also supplied by ciliary 
vessels. They commonly arise from short posterior ciliary arteries 
and also commonly the  arterial circle of Zinn –Haller.
4. RETROLAMINAR REGION – it is the part that lies immediately 
behind the lamia cribrosa. It is supplied by both ciliary and retinal
circulation with the former coming from the recurrent pial vessels. 
Central retinal artery provides centripetal brances from the pial 
plexus and also centrifugal branches.
Axial centrifugal vascular system – it is formed by the inconstant 
branches arising from the intra neural part of central retinal artery. 
However, it is not consistently present in all nerves.
Therefore the main source of blood supply to the optic nerve head 
is the PCA circulation via the peripapillary choroid and the short 
PCAs (or circle of Zinn and Haller). Flourescein angiography 
studies have shown sectoral blo
along with the overall segmental distribution of the PCA 
circulation which helps to explain the segmental visual loss in 
AION.
Figure 5: Picture representing the 
od supply in the ONH which goes 
blood supply of the optic nerve head
Arterial blood supply of the posterior part of the optic nerve
This part of the optic nerve has a peripheral and an axial vascular 
system. 
Peripheral centripetal vascular system- formed by the pial vessels 
which come from collateral arteries arising directly from the ophthalmic 
artery and some its intraorbital branches.4
Axial centrifugal vascular system – formed by branches of central 
retinal artery seen in 75% of cases and the supply of central retinal artery 
may extend 1 to 4 mm behind the site of penetration of central retinal 
artery into the optic nerve and give rise to centrifugal branches.
INTER-INDIVIDUAL VARIATION IN THE BLOOD SUPPLY OF 
THE OPTIC NERVE HEAD 
The pattern of blood supply of the optic nerve head is not identical 
in all eyes. There is a marked variation among individuals which is 
produced by the following factors4 :
1. Variation in anatomical pattern of the arterial blood supply 
2. Variations in the Posterior ciliary artery circulation – there may 
be between one to five PCAs but usually 2 or 3 PCAs are 
usually present. The PCAs enter the eyeball usually medial and 
lateral to the optic nerve and hence they are called as medial 
and lateral PCAs.
Hayreh et al5 have shown that PCAs and their branches have 
segmental distribution in vivo in the choroid as well as in the ONH. 
The medial PCA may supply the entire ONH or it may take no part 
in the blood supply of the ONH and there may be any number of 
variations between these two extremes. The lateral PCA supplies 
the area of ONH not supplied by the medial PCA or vice versa. 
When there is more than one medial or lateral PCA, the area is 
supplied by each and may be only a sector. When the superior PCA 
is present, it accordingly supplies a superior sector. Therefore the 
inter individual variation in number and distribution by the various 
PCAs produces an extremely variable pattern of distribution by the 
PCAs in the optic nerve head. This is very important while dealing 
with ischemic disorders of the ONH.
WATERSHED ZONES IN THE PCA DISTRIBUTION AND 
THEIR LOCATION –
When a tissue is supplied by two or more end-arteries, the border 
between the territories of distribution of any two end arteries is 
called a ‘watershed zone’. The significance is that in the event of a 
fall in the perfusion pressure in the vascular bed of one or more of 
the end arteries, the watershed zone being an area of comparatively 
poor vascularization is most vulnerable to ischaemia. Since PCAs 
and their subdivisions are end arteries in vivo they have watershed 
zones between them.
Ischaemia of the anterior part of optic nerve most commonly 
occurs where there is crowding of nerve fibres and decrease in 
blood supply may merge to decrease perfusion to a severe extent. 
The blood flow within the optic nerve head depends upon several 
factors, the most important of which is blood pressure within the 
vessels.
The blood flow in the ONH is calculated by using the formula6 –
Perfusion pressure = Mean BP – intraocular pressure 
Mean BP = diastolic BP + 1/3 (systolic – diastolic BP)
Therefore, blood flow depends upon – resistance to blood flow, BP 
and intraocular pressure.
Thus, a reduction in blood flow may develop consequent to any of 
the three factors. Transient poor circulation or loss of circulation in 
the optic nerve head can occur due to a transient fall of blood 
pressure below a critical level in its vessels, which in turn in 
susceptible persons could produce AION7. 
Normally there is an auto regulation mechanism that operates in 
the optic nerve and helps to compensate for any decrease for any 
decrease in the blood flow, but it operates only over a critical range 
of perfusion pressure so that with a rise or fall of perfusion 
pressure beyond which this mechanism fails.
Factors leading to the derangement of auto regulation in the ONH 
include systemic and local factors8, aging, arterial hypertension, 
diabetes mellitus, marked hypotension due to any cause, 
atherosclerosis, hypercholesterolemia, arteriosclerosis and 
hyperhomocysteinemia.
ANTERIOR ISCHAEMIC OPTIC NEUROPATHY
It is an optic neuropathy of acute or sub-acute onset which occurs due to 
precarious decrease in blood flow to axons of retinal ganglion cells. It is a 
widespread visually disabling disorder that is commonly seen in the 
middle aged and elderly population. The classical presentation involves 
sudden loss of a part of the visual field. 
There are two clinical types –
1. Arteritic AION
2. Non arteritic AION
ARTERITIC AION 
This type is less common than the non-arteritic type.  It is most 
commonly associated with Giant cell arteritis due to occlusion of 
SPCA leading to decrease in blood flow to proximal part of the optic 
nerve and choroid. Inflammatory response occurs involving the 
medium and large sized arteries. Focal and sectoral granulomatous 
inflammation occurs between the tunica intima and tunica media.
Intravascular inflammation leads to secondary obstruction of the blood 
vessel lumen due to occlusion.
Giant cell arteritis commonly occurs in the elderly population more 
than 50 years of age with a female predilection. It is a systemic 
disease process which presents with – jaw claudication, headache, 
scalp tenderness, weight loss, fatigue, night sweats and polymyalgia 
rheumatica10.
Vision loss is usually severe with visual acuity <6/60 at presentation. 
Some patients experience transient loss of vision preceding the attack. 
On examination, patients usually have pallid optic disc oedema. There 
may be cotton wool spots suggestive of co-existing ischaemia in the 
retina. The optic disc of other eye in arteritic type is most commonly
of normal size with a normal cup. In the non arteritic type, the optic 
disc is smaller in size with a small or no cup11.
In suspected cases of AAION, erythrocyte sedimentation rate along
with platelet count must be ordered. A rise in ESR and CRP has the 
greatest specificity for diagnosis of temporal arteritis.
A definitive diagnosis can be made with temporal artery biopsy.
Risk of involvement of other eye varies from 54 to 95%. Time to 
second eye involvement varies from hours to days. Optic disc oedema 
resolves over four to eight weeks with disc pallor and generalized 
attenuation of arterioles in the posterior pole. 
NON ARTERITIC AION
This entity is more common than AAION. There is higher incidence 
in white population and no gender predilection. Though the exact 
etiology remains unknown, it is thought to be due to stenosis of blood
vessels supplying the proximal part of the optic nerve – direct 
branches of PCA and circle of Zinn-Haller.
Small optic disc with a small cup-to-disc ratio creates a crowding
which causes a compromise in vascular microcirculation. NAAION is 
known occur in patients12 with sleep apnoea, nocturnal hypertension, 
vasculopathic systemic diseases and prothrombotic factors. Other 
known risk factors are systemic hypertension, diabetes mellitus, 
hypercholesterolemia, anaemia.
Ocular risk factors commonly associated include – hypermetropia, 
optic disc drusen, elevated intraocular pressure, presence of disc 
oedema.
Vision loss is less severe than with AAION. Patients present with 
unilateral painless visual loss developing over few hours or days. 
Colour vision loss tends to parallel vision loss. Any type of visual 
field defects may occur, but inferior altitudinal field loss usually 
occurs in majority of the patients.  
On examination, optic disc oedema maybe diffuse or sectoral with 
prominent vasculature and haemorrhages. Pallor of optic disc is less 
common than in arteritic form. The optic disc in the fellow eye is 
observed to be lesser in diameter and exhibits a small or deficient cup 
–“disc at risk”.
Recurrence of NAION in the affected eye occurs in less than 5% of 
cases. In the IONDT approximately 15% of patients developed the 
condition in contra lateral eye within a period of five years13. 
HISTORY AND 
EVALUATION
HISTORY AND EVALUATION
1. Symptoms: Defective vision, headache, presence of scalp 
tenderness, field defects, jaw claudication
2. History 
- Diabetes Mellitus, Hypertension, hyperlipidemia, anaemia, 
connective tissue disorder
- H/O similar episode in the past in same or other eye
3. Clinical Features
AAION - visual loss is usually profound, resulting in either complete 
blindness or extremely poor vision. The loss of vision can occur at any 
time of the day, though it is most commonly observed to occur during the 
night.
Pupil shows relative afferent papillary defect, which can be graded using 
neutral density filters. Graded denomination of the neutral density filter is 
placed in front of the better eye and the measurement of the filter in log 
units which results in equalization of the pupillary reflexes gives the 
numerical magnitude of RAPD. 
Colour vision maybe difficult to assess due to poor vision. But in eyes 
with better visual acuity, it may be observed to be defective. 
On ophthalmoscopic examination, during the initial stages there is optic 
disc oedema which is more in one part of the disc than the other. 
Frequently there are splinter haemorrhages at the disc margin. According 
to a study by Hayreh et al, in 69% of arteritic AION eyes, the optic disc 
has chalky white appearance14. Gradually the disc swelling progresses to 
pallor within two to three months. 
Figure 6 – picture showing surface marking of superficial temporal artery
NA-AION – it usually begins with sudden and painless deterioration of 
vision, which may progress rapidly over few hours to days. It is usually 
reported by the patients on waking up in the morning and classical 
presentation is involvement of lower visual field. 
Pupil shows relative afferent papillary defect. Ophthalmoscopy shows an 
oedematous disc initially with a classic appearance of pallid disc oedema. 
There is no correlation between the extent and severity of optic disc 
pallor and severity of visual loss. The fellow eye typically shows no cup 
or a very small cup.
Figure 7 – Fundus photographs showing optic disc oedema progressing to disc pallor in 
a patient with NAAION
OTHER INVESTIGATIONS
FUNDUS FLOURESCEIN ANGIOGRAPHY – in non arteritic 
AION, during the very early stages of the disease, angiography may 
show filling defects in the optic disc. In contrast, peripapillary choroidal 
filling is not delayed. 
In arteritic AION, this test is extremely helpful in making the diagnosis 
because it shows both the choroid and the optic disc in the area supplied 
by the involved posterior ciliary artery do not fill. 
AUTOMATED PERIMETRY – By Octopus to look for altitudinal field 
defects, the progression of which can be monitored during the follow 
up. 
BLOOD INVESTIGATIONS –
Complete haemogram including Erythrocyte sedimentation rate is 
routinely recommended while investigating patients with ischemic optic 
neuropathy. ESR tends to increase with age. Miller and Green have 
provided a rule for calculation of normal maximum ESR at a given age –
Men – Age in years /2
Women – Age in years +10 / 2
According to a study by Hayreh et al, cut off criteria of 33 mm/1st hour in 
men and 35 mm/1st hour in women may provide a sensitivity  and 
specificity of 92%.
The same study suggested that the sensitivity and specificity of C-
reactive protein in detecting cranial arteritis were 100% and 83 % in men 
and 100% and 79% in women respectively.  
Random blood sugar and lipid profile are also recommended to assess 
etiological associations and for monitoring the treatment.
ROLE OF TEMPORAL ARTERY BIOPSY
This is useful to make a definitive diagnosis of giant cell arteritis. It is 
recommended that biopsy should be done in every case of suspected 
AAION as treatment necessitates high dose of corticosteroids for a longer 
time. It is known that around five percent of temporal artery biopsy 
specimens may be false negative. Reason for this may be partial 
treatment, inadequate sample, or presence of skip lesions. Therefore a 
negative biopsy does not exclude presence of temporal arteritis.  So, in 
cases of strong suspicion, sequential, and bilateral biopsies may be 
performed. Generally 2 to 3 cm biopsy specimen is obtained to avoid 
missing diagnosis due to skip lesions.
It is recommended that treatment with high dose corticosteroids should be 
started immediately before biopsy is performed. However, the biopsy 
must be done within one to two weeks following the beginning of therapy 
because treatment may decrease the inflammation in the biopsy specimen 
rapidly. Histopathological staining of the internal elastic lamina may 
yield additional sensitivity by demonstrating the features of non 
atherosclerotic wall disruption. 
                    
Figure 8 - schematic pict
                
Figure 9 - Histopathology of temporal artery biopsy in giant cell arteritis.
ure showing the pathology of giant cell arteritis.
MANAGEMENT
Visual prognosis for patients with ischaemic optic neuropathy does 
not change much with any form of treatment. Prior to randomized
controlled trials, optic nerve decompression was believed to be useful in 
patients. The role of systemic steroids has also not been clearly 
established.  Most physicians like to give a trial of systemic steroids in 
patients with acute presentation of NA AION. Prognosis for visual 
recovery is usually poor, although occasionally some patients may show 
good visual recovery also15.
On the contrary, the mainstay of treatment in patients with giant cell 
arteritis is in the form of high dose of systemic corticosteroids.
Goal of management in patients with ischaemic optic neuropathy is –
-to establish the diagnosis
-to distinguish between arteritic and non arteritic forms of the disease.
SYSTEMIC CORTICOSTEROID THERAPY
The most important step in all patients above 55 years of age is to rule out 
giant cell arteritis immediately, because it is an emergency which can be 
prevented with aggressive treatment. 
The main objective of treatment is to prevent the loss of vision in the 
fellow eye. The treatment of choice for giant cell arteritis is systemic 
corticosteroids. 
The recommended dose is 1 to 2 grams/ per day of IV Methyl 
prednisolone for three to five days followed by oral tablet prednisolone 
80 mg daily. All patients are maintained on a high dose of oral 
prednisolone till both the ESR and CRP have stabilized at low levels. 
(usually takes 2 to 3 weeks). The CRP comes down much faster than
ESR. There is gradual tapering of prednisolone. It is recommended that 
high doses of oral steroids should be maintained for 4 to 8 weeks and then 
tapered gradually as long as the patient remains symptom free and ESR is 
below 40mm/1st hour.
It is important to remember the side effects of long term use of steroids 
such as gastric ulcers, myopathies, aseptic necrosis of femur, osteoporosis
and worsening of blood sugar control. 
Unlike arteritic AION, there is no established treatment for non arteritic 
AION. Definite evidence of visual improvement has been noted in some 
patients with oral steroids if treated early. 
Role of Aspirin - A study conducted on 131 patients asserted that aspirin 
prevented the occurrence of non arteritic AION in the contra lateral eye. 
Botelho et al, also established that intake of aspirin does not enhance 
final the visual acuity in these subjects. Likewise, a similar study did not 
find any association linking customary aspirin intake and occurrence of 
new non arteritic AION in the other eye. Non arteritic AION is not a 
thromboembolic ailment, but a hypotensive disorder in most of the 
patients. Aspirin does not have any effect on blood pressure or arterial 
hypotension occurring at bed time.
The Ischemic Optic Neuropathy Decompression Trial (IONDT)16 was a 
randomized, single-blind, multicenter trial sponsored by the National Eye 
Institute to assess the safety and efficacy of optic nerve decompression 
surgery in patients with NAION. Analysis of data from patients enrolled 
in the IONDT at 24 months of follow-up confirmed that there was no 
benefit from optic nerve decompression surgery. 
PART - II
AIMS AND 
OBJECTIVES 
AIMS AND OBJECTIVES
Primary Objectives: 
To assess the clinical presentations and visual outcomes of Anterior 
Ischaemic Optic Neuropathy
1. To study the natural history of AION
2. To identify potential risk factors for AION
3. To diagnose and start treatment after systematic evaluation
Secondary objective
To assess visual outcome after treatment of Anterior ischaemic optic 
neuropathy
MATERIALS 
AND 
METHODS
MATERIALS AND METHODS
Subject Selection :
All cases attending Ophthalmology OPD with typical signs and 
symptoms of Anterior ischaemic optic neuropathy in the period of 12
months.
Inclusion Criteria:
Patients with characteristic clinical features of AION such as – sudden
loss of vision, presence of relative afferent pupillary defect, optic disc
oedema, and optic disc margin blurring, defective visual fields
Exclusion Criteria :
1. Patients with multiple sclerosis with or without optic neuritis
2. Presence of infectious /inflammatory disease
3. Clinical features of retinal/vitreous/ other optic nerve pathology that 
could cause defective vision or field changes.
REGISTRATION
NAME:                                                AGE:             SEX:  M/F
OCCUPATION: ADDRESS:
EYE INVOLVED:  RE/ LE
HISTORY OF THE PRESENTING ILLNESS
The common complaints were,
1. Defective vision – nature of onset, whether painless/painful, 
unilateral/bilateral
2. Headache
3. Associated jaw claudication/ scalp tenderness
4. Fever/ night sweats/ fatigue/ weight loss
5. Similar complaints in the past in same or other eye
Details of the progress from onset, the treatment undergone to the 
present state were noted.
PAST HISTORY
H/o systemic diseases like diabetes mellitus, hypertension, stroke, 
transient ischaemic attacks, carotid artery disease, vasculitis, ischaemic 
heart disease, connective tissue disorders, anaemia. 
H/O any long term drug intake like nasal 
decongestants/amiodarone/interferon alpha was noted
PERSONAL HISTORY
Smoking, alcoholism, type of diet.
GENERAL EXAMINATION
General vital data like pulse, blood pressure, peripheral pulses were 
noted 
OCULAR EXAMINATION
1. Induration of temporal artery region, decreased or absent temporal 
artery pulse, any cordlike or firmness/nodularity of temporal artery  
2.  Visual acuity using Snellen’s chart was recorded
3. Extra ocular movements were noted both ductions and versions
4. Pupil size, shape and reaction noted   
5. Anterior segment examined in detail with slit lamp.
6. A dilated fundus and refraction was done.
7. Colour vision using Ishihara pseudoisochromatic plates, intra 
ocular pressure measurement using Goldman applanation 
tonometry were done for all patients.
8. Visual fields using automated perimetry by Octopus.
INVESTIGATIONS:
1. Blood pressure
2. Complete haemogram with ESR
3. Lipid profile
4. C- reactive protein 
5. Colour fundus photography
6. Fundus flourescein angiography if necessary
Complete systemic evaluation by cardiologist and physician were done in 
all cases to rule out systemic associations
FOLLOW UP
Recording the patients complaints whether stable/ improving / worsening
1. Visual acuity
2. Colour vision
3. Visual fields
4. Contrast sensitivity
RESULTS
RESULTS
36 eyes of 35 patients with AION were included in the study. A 
prospective, observational study was conducted over a period of 
one year. 
1. AGE DISTRIBUTION
The following table shows the age distribution in patients with anterior 
ischaemic optic neuropathy.
TABLE – 1
Age group Patients %
41-50 6 17.14
51-60 20 57.14
61-70 8 22.86
71-80 1 2.86
TOTAL 35 100 %
GRAPH – 1
AGE DISTRIBUTION
In our study of 35 patients with AION, the maximum number of patients 
(20) belonged to the age group of 51-60 years. This constituted a 
percentage of 57.14%.  8 patients were from the age group of 61-70 years 
(22.86%) and 6 patients from age group of 41-50 years (17.14%).  One 
patient belonged to the age group of 71-80 years (2.86%).
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In our study, there was a significant gender difference, with 27 females 
(77.14%) out-numbering the males 8 (22.85%).
GRAPH
2. SEX DISTRIBUTION
TABLE – 2
FREQUENCY %
27 77.14
8 22.85
35 100%
-2: SEX DISTRIBUTION
77%
23%
FEMALE MALE
3. LATERALITY
TABLE-3
Right eye Left eye Bilateral Total
21 13 1 35
FREQUENCY
Frequency %
Right eye 22 61.11
Left eye 14 38.89
Total 36 100%
In our study, there was a predominance of involvement of right eye 
21 patients who constituted 60%, over left eye 13 patients who 
constituted 37.14%. One patient - 2.86% had involvement of other 
eye during the study period.
GRAPH-3: LATERALITY
Right eye
Left eye
Both eyes
4. ASSOCIATED RISK FACTORS
TABLE 5
RISK FACTOR Frequency %
Diabetes Mellitus 12 34.28
Systemic 
hypertension 
9 25.71
Diabetes and 
hypertension
4 11.43
Anaemia 2 5.71
Glaucoma 0 0
Smoking 4 11.43
Hyperlipidemia 1 2.86
No risk factor 8 22.86
In our study, 12 patients (34.28%) who presented with AION had a 
history of diabetes mellitus alone. 9 patients, constituting 25.71% 
of the study subjects, were diagnosed patients of systemic 
hypertension. Out of the total 35 subjects, 4 patients (11.43%) were 
found to have both – diabetes mellitus and systemic hypertension. 
4 subjects (11.43%) gave a history of smoking cigarettes/ beedis. 
Anaemia was found to be associated with 2 (5.71%) of the 
subjects. One patient (2.86%) had hyperlipidemia. 8 patients 
(22.86%) who were diagnosed with AION did not have any 
identifiable risk factors attributable to the condition. 
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5. MODE OF ONSET
TABLE 6
MODE FREQUENCY %
SUDDEN 22 62.86
INSIDIOUS 13 37.14
TOTAL 35 100
In our study, 22 subjects constituting 62.86% presented with acute 
onset of symptoms. Whereas 13 patients (37.14%) had an insidious 
onset of the condition.  
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6. PRESENTING SYMPTOMS
TABLE 7
PRESENTING 
SYMPTOM
FREQUENCY %
Defective vision 35 100
Headache 8 22.86
Jaw claudication 0 0
Scalp tenderness 1 2.86
Weight loss/night 
sweats/ fever
1 2.86
Proximal myalgia 0 0
All the subjects included in the study presented with defective 
vision. 8 patients (22.86%) complained of headache. 
GRAPH- 6: PRESENTING SYMPTOMS
One patient (2.86%) had features of scalp tenderness along with 
fever, weight loss and night sweats. These features are usually 
associated with AAION. 
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7. VISUAL ACUITY AT PRESENTATION
TABLE 8
VISUAL ACUITY FREQUENCY %
≤ 1/60 1 2.78
2/60-6/60 25 69.44
6/36-6/24 9 25
6/18-6/12 1 2.78
≥6/9 0 0
TOTAL NO. OF EYES 36 100
Out of the 36 eyes that were studied, 25 eyes had a visual acuity at 
the time of presentation in the range of 2/60-6/60. This constituted 
a maximum of 69.44 %.  The next group consisted of eyes with 
visual acuity between 6/24 to 6/36 (25%). One patient each 
presented with visual acuity between 6/12-6/18 and less than 1/60.
GRAPH 7: VISUAL ACUITY AT THE TIME OF 
PRESENTATION
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8. FUNDUS FINDING ON OPHTHALMOSCOPIC 
EXAMINATION AT THE TIME OF PRESENTATION
TABLE-9
Fundus finding Frequency %
Pallid optic disc 
oedema
19 54.2
Sectoral pallor 8 22.86
Optic atrophy 4 11.42
Splinter 
haemorrhages
3 8.57
The most common ophthalmoscopic sign at presentation was pallid 
disc oedema seen in 19subjects (54.2%). This was followed by 
sectoral disc pallor seen in 8 subjects constituting 22.86%. Splinter 
haemorrhages were observed in 3 subjects (8.57%) and 4 patients 
(11.42%) were seen to have already developed optic atrophy.
GRAPH-8: FUNDUS FINDINGS AT PRESENTATION
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9. VISUAL FIELD DEFECTS ON AUTOMATED 
PERIMETRY AT THE TIME OF PRESENTATION
TABLE 10
FIELD DEFECT FREQUENCY %
Superior altitudinal 5 14.29
Inferior altitudinal 5 14.29
Superior arcuate 4 11.43
Inferior arcuate 4 11.43
Not possible 17 48.57
Due to poor visual acuity at the time of presentation, in 48.57% of 
the patients, evaluation of visual fields by automated perimetry was 
not possible. 5 patients each were found to have superior and 
inferior altitudinal field defects. 4 patients each had superior and 
inferior arcuate field defects.
GRAPH 9: VISUAL FIELD DEFECTS AT THE TIME OF 
PREENTATION
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10.  INVOLVEMENT OF THE FELLOW EYE
TABLE 11
PREVIOUS 
EPISODE IN
FELLOW EYE
PATIENTS
PRESENT 1
ABSENT 34 
TOTAL 35
Out of the 35 subjects, only one patient reported involvement of the 
other eye with similar complaints earlier. The patient was a middle aged 
female with history of diabetes mellitus and hypertension.
Treatment 
After ocular and systemic examination, all patients underwent relevant 
investigations. Following this, they were started on intravenous methyl 
prednisolone 1 gram in two divided doses for three days followed by oral 
prednisolone 60 mg once daily. This was continued for one week and 
tapered by ten milligrams per week and stopped after a period of 6 weeks.
11. VISUAL OUTCOME FOLLOWING TREATMENT
TABLE 12
VISUAL ACUITY FREQUENCY %
≤ 1/60 1 2.78
2/60-6/60 15 41.67
6/36-6/24 18 50
6/18-6/12 2 5.56
≥6/9 0 0
TOTAL NO. OF EYES 36 100
After starting on treatment, visual acuity measured at the end of six 
months showed that – 18 out of the 36 treated eyes (50%) had a 
visual acuity between 6/24 to 6/36. 
41.67% of the patients had a final visual acuity between 2/60 to 
6/60. One patient still had a visual acuity of less than 1/60 while 
two patients (5.56%) recovered visual acuity up to 6/12.
GRAPH-10: VISUAL OUTCOME AFTER TREATMENT
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12. VISUAL OUTCOME IN DIABETIC PATIENTS
TABLE 13
VISUAL 
ACUITY 
>6/60
VISUAL 
ACUITY 
≤6/60
TOTAL
P =0.0048
DIABETIC 2 14 16
NON 
DIABETIC
12 7 19
TOTAL 14 21 35
Out of the 35 subjects included in the study, 16 patients were diabetic and 
19 were non-diabetic. On comparing the visual outcome among both the 
groups it was observed that, only 2 out of the 16 subjects with diabetes 
mellitus improved with a visual acuity of more than 6/60 constituting 
12.5%. A majority of 14 of the diabetics (87.5%) did not have 
improvement in visual acuity following treatment. 
Among the 19 non-diabetic individuals, 12 of them had an improvement 
in visual acuity (63.16%) to more than 6/6
(36.84%) did not have any visual improvement.
P value is 0.0048 which is statistically significant. Thus visual outcome 
was poorer in diabetic than non
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13.  VISUAL OUTCOME AMONG HYPERTENSIVE 
PATIENTS
TABLE 14
VISUAL 
ACUITY 
≤6/60
VISUAL 
ACUITY 
>6/60
TOTAL
P =0.199
HYPERTENSIVE 2 10 12
NON 
HYPERTENSIVE
16 7 23
TOTAL 18 17 35
Among the 35 patients, 12 were known hypertensive patients on 
treatment. 2 out of these 12 patients (16.67%) had a final visual outcome 
of less than 6/60. The remaining 10 (83.33%) had a final visual acuity of 
more than 6/60.
Among the 23 patients who did not have hypertension, 16 of them 
(69.57%) had a visual acuity of less than 6/60 even after treatment. While 
the remaining 7 patients (30.43%) had a better visual outcome. 
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DISCUSSION
DISCUSSION
1. AGE
In this study, 35 patients with anterior ischaemic optic neuropathy 
were included.  57.14 % of the patients belonged to the age group 
of 51- 60 years. 22.86% belonged to the age group of 61-70 years.
Mean age of onset was around 56.9 years. The oldest patient was 
71 years old and the youngest patient was aged 41years.
AION is typically a disease the middle aged and the elderly 
population with most of the studies reporting a maximum incidence 
in 60- 70 years age range17. Younger patients presenting with 
symptoms of this disease must be thoroughly evaluated for the
presence of systemic and ocular risk factors which need to be 
addressed immediately to protect the fellow eye from getting 
involved.
2. SEX DISTRIBUTION 
In our study, there was a significant gender difference with 77.14% 
of the patients being female while only 22.85% were males. In 
most of the previous studies, equal incidence rates were noted 
among male and female subjects18. 
3. LATERALITY
Our study showed a predominance of right eye over left eye 
which does not co-relate with previous studies. Only 2.86% 
percent of the study population gave history of involvement of 
the fellow eye with similar complaints.  
In the ischaemic optic neuropathy decompression trial 
(IONDT), it was observed that 23% of subjects had a pale optic 
disc in the contra lateral eye which suggested a possibility of 
previous episode of AION. 
4. ASSOCIATED RISK FACTORS
34.28% of the patients with AION were known diabetics on 
treatment. Systemic hypertension was also a risk factor 
constituting 25.71 % of the patients.  11.43% of the subjects had 
both diabetes and hypertension.  5.71% were anaemic. 22.86% 
of the subjects did not have any of the common identified risk 
factors.19
Other studies 19reported association of diabetes mellitus in 10 to 
31%, systemic hypertension among 26 to 47% of the subjects.
Thus diabetes was more predominant association among our 
patients.
5. MODE OF ONSET
62.86% of the patients had an acute onset of painless loss of 
vision which is a characteristic feature of this disease.
6. VISUAL ACUITY AT THE TIME OF PRESENTATION 
All patients in the study presented with defective vision. The 
visual loss was most commonly sudden in onset, painless and 
was in the range of 2/60 to 6/60 in 69.44%. This was 
comparable to other studies conducted by Atkins et al which 
reported similar visual acuity at the time of presentation in 35 to 
53% of the patients included.
7. OPHTHALMOSCOPIC FINDINGS 
54.2% of the subjects had a pallid disc oedema followed by
22.86% patients having sectoral disc pallor. Splinter 
haemorrhages were observed in 8.57% of the subjects.
8. VISUAL FIELD DEFECTS ON AUTOMATED PERIMETRY 
AT THE TIME OF PRESENTATION
Due to poor visual acuity at the time of presentation, it was not possible 
to examine visual fields in 48.57% of the subjects. 
Among the patients in whom visual field examination was possible and 
the fields were reliable, 27.77% showed superior and inferior altitudinal 
field defects respectively. 22.22 % showed superior and inferior arcuate 
field defects. 
The classic presentation of visual field defects described in literature is an 
inferior altitudinal field defect. Central scotomas, quadrantic or arcuate 
defects may also be observed. Hayreh and Podhajsky have reported20
inferior altitudinal field defects in 57% of their study subjects. 
9. VISUAL OUTCOME FOLLOWING TREATMENT
50% of the patients included in the study reported an improvement in 
visual acuity between 6/24 and 6/36. 
41. 67% still had a poor visual outcome of <6/60. In a study reported by 
Atkins et al, more than half of the subjects ended up with a vision of 
<6/60 at the end of the follow up period. 
Among the diabetic patients included in the study, it was observed that 
87.5% did not have any significant improvement in visual acuity. 63.67% 
of the non diabetic subjects showed an improvement >6/60. The p value 
by Pearson’s Chi square test was found to be 0.0048 which is statistically 
significant. This means that the presence of diabetes mellitus among 
patients with AION is associated with a poorer visual outcome than in 
patients without it. 
Hayreh and Zimmermann reported that final visual acuity did not differ 
significantly among patients with and without diabetes.
Among the patients with systemic hypertension, 16.67% had a final 
visual outcome of less than 6/60. 83.33% had a visual acuity better than 
6/60. P value was found to be more than 0.05. Hence the association was 
not statistically significant.
CONCLUSION
CONCLUSION
1. Anterior ischaemic optic neuropathy affects the middle aged and 
elderly population, with 51 to 60 years being the most affected age 
group in our study.
2. Females were more commonly affected than males. Female to male 
ratio was around 3.5:1.
3. There was a predominance of involvement of right eye over that of 
left eye in our study. 
4. Only 2.86% of the patients showed optic disc pallor in other eye 
due to previous episode of AION.
5. Diabetes mellitus and systemic hypertension are associated risk 
factors with the development of AION. Diabetes was more 
predominant risk factor in our study.
6. 69.44% of the patients presented with a very poor visual acuity in 
the range of 2/60 to 6/60.
7. Pallid disc oedema was the most common ophthalmoscopic finding 
followed by sectoral pallor of optic disc and splinter haemorrhages.
8. It was not possible to do an automated perimetry to evaluate visual 
fields in 48.57% of the patients due to poor visual acuity at the 
time of presentation. 
9. Among the patients in whom it was possible, superior and inferior 
altitudinal field defects were found in equal number of patients.
10. In 67% of the patients, visual acuity remained less than 6/60 in 
spite of timely treatment with corticosteroids.
11.The presence of diabetes mellitus is associated with a poor visual 
outcome following treatment.
12.Presence of hypertension/anaemia/ hyperlipidemia did not affect 
the final visual outcome.
Anterior ischaemic optic neuropathy is associated with a poor 
visual outcome in spite of timely intervention with corticosteroids. 
It should always be considered in the differential diagnosis of 
painless loss of vision associated with optic disc oedema. All 
patients must be thoroughly evaluated for systemic risk factors and 
treated promptly to prevent the occurrence of ischaemic optic 
neuropathy in the other eye.
PART III
PROFORMA
Clinical study on Anterior ischaemic optic neuropathy
Name –
Age – Sex –
O.P/I.P No. –
Date
Address –
Contact No. –
Unit –
Diagnosis –
Chief complaints –
1. Loss of vision – Onset  -
                                             Duration –
                                             Progression –
                                             Associated pain –
2. Headache –
3. Jaw claudication –
4. Scalp tenderness –
5. Similar episode in the other eye/ same eye -  
6. Weight loss/ fatigue/ night sweats -
Relevant past history –
1. Diabetes mellitus - duration –
Treatment -
2. Systemic hypertension - duration –
Treatment –
3. Glaucoma –
4. Hyperlipidemia –
5. Anaemia –
6. Joint pains –
7. Drug intake –
8. Alcohol intake –
9. Smoking –
10. Fever / infections –
EXAMINATION –
General examination:
Built –
Nourishment –
Pallor –
B.P -   
Cardiovascular system:
Respiratory system: 
Abdominal system:
Central nervous system: higher functions
Cranial nerves
Motor system
Sensory system
Cerebellum
Examination of temporal artery region – temporal artery pulsation –
Induration –
Firmness/ nodularity of temporal artery-
OCULAR EXAMINATION -
RE LE
Visual acuity
Lids 
Conjunctiva 
Cornea 
AC
Pupil Normal/RAPD
Direct
Indirect 
Normal/RAPD
Direct
Indirect
Lens 
IOP
Colour vision 
Fundus examination –
Direct ophthalmoscopy Media
Optic disc
CD ratio
Indirect ophthalmoscopy 
Fields –
RE LE
Manual
AP
Inference
FFA –
PROVISIONAL DIAGNOSIS –
BLOOD INVESTIGATIONS –
1. Complete haemogram
TC
DC    N  L  M  E  B 
ESR 
Hb
2. RBS -
3. Total cholesterol –
4. C- reactive protein 
Cardiologist opinion –
MANAGEMENT –
Date Treatment 
IVMP
T. Predni
T. Aspirin
Follow up -
Date Visual 
acuity 
Field of 
vision 
Colour 
vision
Fundus Pupil
RE LE RE LE     RE LE
Admission 
2 weeks 
2 months
6 months 
KEY TO MASTER CHART
M      -           MALE
F        -           FEMALE
RE - RIGHT EYE
LE - LEFT EYE
NAD - NO ABNORMALITY DETECTED
DM - DIABETIC MELLITUS
HTN - HYPERTENSION
VN     - VISION
ESR - ERYTHROCYTE SEDIMENTATION RATE
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